Emily Rachal
Nurse Practitioner · Wayne, MINPI 1306089735
Payments from drug & device makers
Across 235 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$1K
- Sunovion Pharmaceuticals Inc.$597
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$482
- AbbVie$425
- Alkermes, Inc.$346
- Otsuka America Pharmaceutical, Inc.$313
- plus $967 from 17 others
What the payments were for
- Food & beverage$4,48699%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 64 | $1,404 |
| Sunovion Pharmaceuticals Inc. | 44 | $597 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $482 |
| AbbVie | 24 | $425 |
| Alkermes, Inc. | 11 | $346 |
| Otsuka America Pharmaceutical, Inc. | 19 | $313 |
| Teva Pharmaceuticals USA, Inc. | 7 | $209 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $128 |
| Vanda Pharmaceuticals Inc. | 6 | $110 |
| Neurocrine Biosciences, Inc. | 5 | $82 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Johnson & Johnson | 4 | $72 |
| Avanir Pharmaceuticals, Inc. | 3 | $59 |
| Noven Therapeutics, LLC | 3 | $40 |
| Almatica Pharma LLC | 2 | $39 |
| Corium, LLC | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $21 |
| Indivior Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| OWP Pharmaceuticals, Inc. | 1 | $13 |
| Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$479
How this compares
$4,533 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 77 | $244,734 |
| Clozapine OdtClozapine | 285 | $172,281 |
| RexultiBrexpiprazole | 110 | $161,170 |
| AustedoDeutetrabenazine | 22 | $96,798 |
| FanaptIloperidone | 36 | $61,343 |
| Clozapine | 643 | $48,703 |
| VraylarCariprazine Hcl | 34 | $47,977 |
| NuedextaDextromethorphan Hbr/Quinidine | 27 | $42,331 |
| Paliperidone ErPaliperidone | 224 | $36,934 |
| Risperidone OdtRisperidone | 142 | $30,044 |
| Risperdal ConstaRisperidone Microspheres | 12 | $23,610 |
| Aripiprazole | 338 | $21,597 |
| Topiramate ErTopiramate | 24 | $21,107 |
| Naltrexone Hcl | 342 | $20,932 |
| Divalproex Sodium | 846 | $19,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $72 | $268,34489 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $313 | $161,170110 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $209 | $96,79822 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $110 | $61,34336 claims |
| AbbVieVraylar | $425 | $47,97734 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $59 | $42,33127 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $128 | $21,58448 claims |
| Almatica Pharma LLCSertraline Hcl | $39 | $4,705483 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Wayne
- Nekea FranklinWayne$18K
- Davida KrugerDetroit$1.8M
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Abubakir BabanDearborn$143K
- Elizabeth KirshnerAnn Arbor$119K
- Lisa Astalos ChismWoodhaven$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.